Comparison of Bone Marrow Aspirate and Autologous Protein Solution Collected With Traditional Zimmer Biomet Biocue and Novel Marrow Cellutions Systems in Patients Undergoing Minimally Invasive Hip Repair

What this Trial Is About

Researchers are evaluating two different systems for collecting bone marrow liquid in patients aged 18 to 50 years with confirmed bone loss of the hip, such as subchondral bone cysts or avascular necrosis. The study compares the traditional Zimmer Biomet Biocue system, which is currently used in standard care for minimally invasive hip repair, with the novel Marrow Cellutions system™. This study aims to understand the differences in cellular and molecular contents collected by the two methods. Participants will undergo bone marrow liquid collection from both hips during a minimally invasive hip repair procedure. The surgical hip will be sampled using the Zimmer Biomet Biocue system, and the non-surgical hip will be sampled with the Marrow Cellutions™ system. The collected bone marrow liquids are then processed to concentrate cells and molecules. Only the concentration from the Zimmer Biomet Biocue system will be delivered to the surgical site to aid healing. The samples from the Marrow Cellutions™ system and from a separate blood draw processed into an autologous protein solution using the Zimmer Biomet Plasmax system will be sent to a laboratory for detailed analysis. Participants will be monitored over six months to assess the number of stem cells, cytokines, and growth factors collected by each aspiration method. The study involves routine blood draws and analysis of collected samples but does not deliver the protein solution to the patient. This research will provide information on the cellular makeup of bone marrow collected by different devices, potentially informing future treatments for hip bone loss conditions.

Marrow Cellution™ vs. Traditional BMA Harvest Project